| Elizabeth Baker Golpira, MD | |
|
100 Kingsley Ln, Suite 400, Norfolk, VA 23505-4604 | |
| (757) 451-0929 | |
| (757) 423-4901 |
| Full Name | Elizabeth Baker Golpira |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 25 Years |
| Location | 100 Kingsley Ln, Norfolk, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396852174 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0101234652 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bon Secours Maryview Medical Center | Portsmouth, VA | Hospital |
| Sentara Leigh Hospital | Norfolk, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-atlantic Womens Care Plc | 8820998156 | 140 |
News Archive
A new genetic test targeting the most common types of muscular dystrophy-those caused by mutations in the dystrophin gene-is far quicker with greater accuracy and sensitivity than existing tests.
Rutgers Cancer Institute of New Jersey researcher Hossein Khiabanian, PhD, has received a $600,000 Translational Award from the V Foundation for Cancer Research to study chronic lymphocytic leukemia with the aim of developing research models that may help investigators better understand how CLL cells are influenced by new therapies.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
Pancreatic tumors can be identified by a readily detectable marker that shows promise as a basis for immune therapy against the disease, according to research at Washington University School of Medicine in St. Louis.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.
› Verified 9 days ago
| Entity Name | Mid-atlantic Womens Care Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699365072 PECOS PAC ID: 8820998156 Enrollment ID: O20040115000607 |
News Archive
A new genetic test targeting the most common types of muscular dystrophy-those caused by mutations in the dystrophin gene-is far quicker with greater accuracy and sensitivity than existing tests.
Rutgers Cancer Institute of New Jersey researcher Hossein Khiabanian, PhD, has received a $600,000 Translational Award from the V Foundation for Cancer Research to study chronic lymphocytic leukemia with the aim of developing research models that may help investigators better understand how CLL cells are influenced by new therapies.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
Pancreatic tumors can be identified by a readily detectable marker that shows promise as a basis for immune therapy against the disease, according to research at Washington University School of Medicine in St. Louis.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.
› Verified 9 days ago
| Entity Name | Mid-atlantic Womens Care Plc |
|---|---|
| Entity Type | Part B Supplier - Mammography Center |
| Entity Identifiers | NPI Number: 1699365072 PECOS PAC ID: 8820998156 Enrollment ID: O20080611000246 |
News Archive
A new genetic test targeting the most common types of muscular dystrophy-those caused by mutations in the dystrophin gene-is far quicker with greater accuracy and sensitivity than existing tests.
Rutgers Cancer Institute of New Jersey researcher Hossein Khiabanian, PhD, has received a $600,000 Translational Award from the V Foundation for Cancer Research to study chronic lymphocytic leukemia with the aim of developing research models that may help investigators better understand how CLL cells are influenced by new therapies.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
Pancreatic tumors can be identified by a readily detectable marker that shows promise as a basis for immune therapy against the disease, according to research at Washington University School of Medicine in St. Louis.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Baker Golpira, MD 100 Kingsley Ln, Suite 400, Norfolk, VA 23505-4604 Ph: (757) 451-0929 | Elizabeth Baker Golpira, MD 100 Kingsley Ln, Suite 400, Norfolk, VA 23505-4604 Ph: (757) 451-0929 |
News Archive
A new genetic test targeting the most common types of muscular dystrophy-those caused by mutations in the dystrophin gene-is far quicker with greater accuracy and sensitivity than existing tests.
Rutgers Cancer Institute of New Jersey researcher Hossein Khiabanian, PhD, has received a $600,000 Translational Award from the V Foundation for Cancer Research to study chronic lymphocytic leukemia with the aim of developing research models that may help investigators better understand how CLL cells are influenced by new therapies.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
Pancreatic tumors can be identified by a readily detectable marker that shows promise as a basis for immune therapy against the disease, according to research at Washington University School of Medicine in St. Louis.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.
› Verified 9 days ago
Daniel L Noffsinger, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 880 Kempsville Rd, Suite 2200, Norfolk, VA 23502 Phone: 757-466-6350 Fax: 757-466-9262 | |
Anna Hayes Nutter, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 825 Fairfax Ave, Hofheimer Hall. Suite 528, Norfolk, VA 23507 Phone: 757-446-7350 | |
Negar Nikki Sadr, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 844 Kempsville Rd, Suite 208, Norfolk, VA 23502 Phone: 757-461-3890 Fax: 757-461-0836 | |
Alana Michelle Chakrabarti, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 825 Fairfax Ave Ste 310, Norfolk, VA 23507 Phone: 757-446-7979 Fax: 757-446-8907 | |
Malena C Sample, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5280 Henneman Dr, Norfolk, VA 23513 Phone: 757-395-4455 Fax: 757-233-1792 | |
Theresa W Whibley, M.D Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 400 Gresham Dr, Suite 811, Norfolk, VA 23507 Phone: 757-623-3845 Fax: 757-623-0547 | |
Gloria T Too, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 825 Fairfax Ave, Suite 310, Norfolk, VA 23507 Phone: 757-446-7900 Fax: 757-446-7464 |